BETA-BLOCKERS AND RENOPROTECTION: THE POTENTIAL OF CARVEDILOL

BETA-BLOCKERS AND RENOPROTECTION: THE POTENTIAL OF CARVEDILOL

The review presented the importance of carvedilol using in terms of renoprotection in renal dysfunction at the pre-dialysis stage of the disease in order to reduce the risk of progression of chronic kidney diseases (CKD) and the development of cardiovascular complications. Immune and non-immune mech...

Full description

Bibliographic Details
Main Authors:	I. T. Murkamilov, I. S. Sabirov, V. V. Fomin, F. A. Yusupov
Format:	Article
Language:	English
Published:	Столичная издательская компания 2017-07-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	beta-adrenoblockers carvedilol chronic kidney disease cardiovascular diseases
Online Access:	https://www.rpcardio.online/jour/article/view/1496

Similar Items

Long-term carvedilol therapy effects on left ventricular remodeling and glycemia in patients with chronic heart failure and Type 2 diabetes mellitus
by: R. R. Samedov, et al.
Published: (2008-02-01)

ESTIMATION OF CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC CARVEDILOLS IN PATIENTS WITH HYPERTENSION OF 1-2 GRADES
by: E. I. Bambysheva, et al.
Published: (2016-01-01)

Cardioselective beta-adrenoreceptor blockade with betaxolol in cardiovascular therapy
by: D. V. Duplyakov
Published: (2009-08-01)

BETA-ADRENOBLOCKERS AND PLATELET AGGREGATION. CARVEDILOL
by: A. N. Zakirova, et al.
Published: (2016-01-01)

Carvedilol and bisoprolol effectiveness in patients with myocardial infarction and heart failure
by: A. I. Chesnikova, et al.
Published: (2008-06-01)

COMPARISON OF THE INFLUENCE OF LONG-TERM TREATMENT BASED ON CARVEDILOL OR BISOPROLOL ON METABOLIC PARAMETERS IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT OR OBESITY RESULTS OF THE RANDOMIZED OPEN-LABEL PARALLEL-GROUPS STEPPED TRIAL CABRIOLET (PART I)
by: S. Y. Martsevich, et al.
Published: (2015-12-01)

CLINICAL PRACTICE OF BETA-BLOCKERS USAGE IN PATIENTS WITH CARDIOVASCULAR AND CHRONIC RESPIRATORY DISEASES. DATA OF OUTPATIENT REGISTRIES PROFILE AND RECVASA
by: S. Yu. Martsevich, et al.
Published: (2017-09-01)

COMPARISON OF THE INFLUENCE OF LONG-TERM TREATMENT BASED ON CARVEDILOL OR BISOPROLOL ON METABOLIC PARAMETERS AND ERECTILE FUNCTION IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT OR OBESITY RESULTS OF THE RANDOMIZED OPEN-LABEL PARALLEL-GROUPS STEPPED TRIAL CABRIOLET (PART 2)
by: S. Y. Martsevich, et al.
Published: (2015-12-01)

Beta-adrenoblockers in cardiology practice
by: A. A. Garganeeva
Published: (2010-10-01)

Differential beta-adrenoblocker therapy in chronic heart failure
by: S. N. Tereshchenko, et al.
Published: (1970-01-01)

Current guidelines for β-adrenoblockers use in cardiovascular diseases: focus on metoprolol succinate CR/XL: A review
by: Marina G. Bubnova
Published: (2022-07-01)

Stable coronary heart disease treatment: focus on beta-adrenoblockers
by: V. I. Makolkin
Published: (2008-12-01)

Beta-adrenoblocker in heart failure: bisoprolol role
by: Yu. V. Lukina, et al.
Published: (1970-01-01)

EFFECTS OF BETA-BLOCKER METOPROLOL ON QUALITY OF LIFE IN ELDERLY PATIENTS WITH CHRONIC HEART FAILURE
by: I. V. Vologdina
Published: (2015-12-01)

R-carvedilol, a potential new therapy for Alzheimer’s disease
by: Jinjing Yao, et al.
Published: (2022-11-01)

Status and function of betaDadrenoreceptors and their modification during betaDblocker treatment in patients with arterial hypertension and chronic heart failure
by: O. A. Maneshina, et al.
Published: (2005-10-01)

Beta-blockers, and real clinical practice in Russia: the gap between the understanding of the doses of beta-blockers and subsequent prognosis in patients with cardiovascular disease
by: I V Fomin, et al.
Published: (2017-12-01)

Corrigendum: R-carvedilol, a potential new therapy for Alzheimer’s disease
by: Jinjing Yao, et al.
Published: (2023-01-01)

Choosing therapeutic tactics in pregnant women with chronic arterial hypertension: the priorities
by: N. G. Pivonova, et al.
Published: (2009-08-01)

Current position of beta-adrenoblockers in coronary heart disease management: information for clinicians
by: I. A. Libov, et al.
Published: (2009-04-01)

HEART FAILURE, DIABETES, BETA-BLOCKERS AND RISK OF HYPOGLYCEMIA
by: A. A. Aleksandrov, et al.
Published: (2016-01-01)

Differential approach in selecting beta-adrenoblocker therapy for patients with chronic heart failure and anaemia
by: T. M. Uskach, et al.
Published: (2012-04-01)

METOPROLOL AND CARVEDILOL IN THERAPY OF ACUTE MYOCARDIAL INFARCTION: WHEN AND WHICH DRUG TO PREFER
by: B. N. Garifullin, et al.
Published: (2016-01-01)

The β-blocker carvedilol and the benznidazole modulate the cardiac immune response in the acute infection induced by Colombian strain of the Trypanosoma cruzi
by: Aline Luciano Horta, et al.
Published: (2018-10-01)

THE ROLE OF CARVEDILOL IN THE PREVENTION OF CARDIOMYOCYTE APOPTOSIS CAUSED BY ACUTE MYOCARDIAL INFARCTION
by: A. N. Zakirova, et al.
Published: (2017-12-01)

Oxidative and physiological effects of carvedilol, a beta–blocker, in Daphnia magna
by: Engin Seker
Published: (2024-11-01)

Beta-adrenoblockers in coronary heart disease patients. Evidencebased medicine data
by: A. E. Radzevich, et al.
Published: (1970-01-01)

CARDIO-SELECTIVE BETA-ADRENOBLOCKER SAFETY IN CARDIOVASCULAR DISEASE TREATMENT AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: B. V. Trapeznikova, et al.
Published: (2010-06-01)

Carvedilol and its combination with digoxin for heart rate control in patients with persistent atrial fibrillation and chronic heart failure
by: S. N. Tereshchenko, et al.
Published: (1970-01-01)

COMPARISON OF THERAPIES BASED ON CARVEDILOL AND METOPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT OR OBESITY. THE FIRST RESULTS OF CAMELLIA TRIAL
by: S. Y. Martsevich, et al.
Published: (2016-01-01)

COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL
by: S. Y. Martsevich, et al.
Published: (2016-01-01)

Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
by: Tilman Sauerbruch, et al.
Published: (2023-01-01)

URODYNAMIC EFFECTS OF BETA-ADRENOBLOCKERS: NEBIVOLOL ADVANTAGES
by: M. P. Savenkov, et al.
Published: (2016-01-01)

Rational pharmacotherapy of chronic obstructive pulmonary disease in elderly patients with cardiac arrhythmias: the role of a betaadrenoblocker bisoprolol
by: D. A. Kadaeva, et al.
Published: (2010-10-01)

Disorders of the central nervous system cognitive and mnestic functions in genetic arterial hypertension and with the use of beta-blockers of different generations
by: A. O. Svitlytskyi, et al.
Published: (2024-09-01)

Differential beta-adrenoblocker therapy in chronic heart failure: the role of age, gender, and co-morbidity
by: S. N. Tereshchenko, et al.
Published: (2009-10-01)

Long-term hemodynamic response of carvedilol and simvastatin in compensated versus decompensated chronic liver disease with portal hypertension
by: Shaheen Nazir, et al.
Published: (2024-03-01)

Repositioning of the β-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome
by: Wei-Ting Wong, et al.
Published: (2018-08-01)

Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention
by: Md Abdullah Shamim, et al.
Published: (2023-03-01)

Carvedilol therapy effects on structural and electric remodeling in chronic heart failure
by: E. V. Minakov, et al.
Published: (2008-02-01)